Piper Sandler Reiterates Overweight on Revance Therapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Revance Therapeutics (NASDAQ:RVNC) but lowered the price target from $20 to $11.

May 10, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler's reiteration of an Overweight rating on RVNC with a reduced price target suggests continued confidence in the company's fundamentals but acknowledges near-term challenges or valuation adjustments.
The Overweight rating indicates a positive outlook on the stock, suggesting that Piper Sandler believes RVNC will outperform its sector or the market. However, lowering the price target could reflect revised expectations for the company's future growth prospects, potential challenges it may face, or a broader market recalibration. This adjustment is likely to have a mixed short-term impact on RVNC's stock price, as the market digests the positive endorsement against the backdrop of a lowered valuation benchmark.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90